Myochron is developing a cloud-based platform that utilizes individualized electrical dyssynchrony mapping to optimize cardiac resynchronization therapy (CRT) for heart failure patients. By tailoring therapy to each patient's unique anatomy and physiology, Myochron aims to improve CRT response rates, thereby enhancing heart function and reducing healthcare costs associated with non-response.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiac Resynchronization Therapy (CRT) aims to improve heart function in heart failure patients, but a significant portion do not respond optimally to the therapy. Many non-responders do not undergo beneficial changes to their device settings, leading to suboptimal outcomes. This results in increased healthcare costs and a failure to improve the patient's condition.
Solution
Myochron is developing a cloud-based platform that utilizes individualized electrical dyssynchrony mapping to optimize CRT for heart failure patients. The platform aims to tailor therapy to each patient's unique anatomy and physiology, improving CRT response rates and enhancing heart function. By identifying the optimal programming for each patient, Myochron's Cardiac Synchronization Index (CRI) informs clinicians on how to achieve maximal response. The platform integrates into existing clinical workflows, allowing for optimization during standard device check visits.
Target Audience
The primary users are cardiologists and electrophysiologists who treat heart failure patients with CRT devices.
Features
- Cloud-based platform for remote access and collaboration
- Individualized electrical dyssynchrony maps based on the Cardiac Synchronization Index (CRI)
- Recommendations for optimal device programming tailored to each patient's condition
- Seamless integration into existing clinical workflows and standard device check visits
- Capability to individualize both new and existing CRT devices